Primary Care Physicians Can Prescribe Repatha (Evolocumab)
Yes, primary care physicians can prescribe Repatha (evolocumab)—there are no regulatory or FDA restrictions limiting prescribing authority to cardiologists only. The FDA approval and current guidelines do not specify prescriber specialty requirements 1.
Prescribing Authority
The FDA-approved labeling for Repatha does not restrict prescribing by specialty 1. Any licensed physician with prescribing authority, including primary care physicians, can prescribe PCSK9 inhibitors like evolocumab for FDA-approved indications, which include:
- Adults with established cardiovascular disease to reduce CV events
- Adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia)
- Pediatric patients ≥10 years with HeFH or HoFH
- As adjunct to diet and maximally tolerated statin therapy 2
Clinical Practice Reality
The 2022 ACC Expert Consensus Decision Pathway explicitly frames PCSK9 inhibitor use within the context of lipid management that can be initiated by any qualified clinician 2. The guidelines discuss dosing, monitoring, and patient selection criteria without restricting these decisions to cardiologists. The Canadian Cardiovascular Society 2021 guidelines similarly present treatment algorithms applicable to general practice settings 3.
Practical Considerations
What PCPs Should Know:
- Prior authorization is typically required and can be burdensome 2
- Cost considerations are significant—this often drives the need for documentation of:
- Maximally tolerated statin therapy
- Addition of ezetimibe when appropriate
- Persistent LDL-C elevation despite therapy
- Clear cardiovascular risk profile
When to Consider Prescribing:
For patients with established ASCVD:
- LDL-C ≥70 mg/dL (1.8 mmol/L) on maximally tolerated statin + ezetimibe 4
- Dosing: 140 mg SC every 2 weeks OR 420 mg SC monthly 2, 1
For patients with severe primary hypercholesterolemia:
- Baseline LDL-C ≥220 mg/dL and current LDL-C ≥130 mg/dL on maximal statin + ezetimibe 5
For heterozygous FH patients:
- Age 30-75 years with LDL-C ≥100 mg/dL on maximal statin + ezetimibe 5
Common Pitfalls to Avoid
Insurance denial due to inadequate documentation: Ensure clear documentation of statin intolerance or inadequate response at maximally tolerated doses, and trial of ezetimibe when appropriate
Latex sensitivity: Repatha is available in formulations both with and without natural rubber latex in the needle cover—prescribe the appropriate version 1
Patient education gaps: The medication requires subcutaneous self-injection every 2 weeks or monthly. Ensure patients understand administration technique (takes up to 15 seconds with autoinjector) 1
Monitoring: Assess LDL-C as early as 4 weeks after initiation to confirm response 1
Collaboration vs. Independent Management
While PCPs can prescribe Repatha independently, collaboration with cardiology may be beneficial for:
- Complex familial hypercholesterolemia cases (especially homozygous FH)
- Patients on LDL apheresis requiring dose coordination
- Unclear cardiovascular risk stratification
- Navigating complex prior authorization denials
The evidence shows high patient and physician satisfaction with evolocumab when prescribed (96.1% and 90.8% respectively), with physicians satisfied with LDL-C control and outcomes 6. Recent data demonstrates significant cardiovascular benefit even in older patients ≥75 years (HR 0.79 for primary endpoint) and in primary prevention populations without prior MI or stroke 7, 8.
Bottom line: PCPs have full prescribing authority for Repatha. The decision should be based on clinical appropriateness, guideline-directed indications, and practical ability to navigate prior authorization requirements—not on specialty restrictions that don't exist.